This inventor holds 2 USPTO granted patents. Top assignee: Spring Bioscience Corporation. Active years: 2006-2009.
Company Filing History:
Years Active: 2006-2009
Title: Innovations by Haiying Xia in Monoclonal Antibody Development
Introduction
Haiying Xia is an accomplished inventor based in Union City, CA (US). He has made significant contributions to the field of immunology through his innovative work on monoclonal antibodies. With a total of 2 patents, his research focuses on developing high-affinity antibodies that can improve diagnostic and therapeutic applications in breast cancer.
Latest Patents
Haiying Xia's latest patents include two groundbreaking innovations. The first patent is for a high-affinity monoclonal antibody that recognizes the progesterone receptor (PR). This invention presents a method for creating the antibody, which boasts the advantage of not requiring target retrieval in immunohistochemistry. The lagomorph-derived monoclonal antibody (clone SP2) demonstrates a very low background in immunohistochemistry, making it a promising alternative to existing PR antibodies. Comparative studies with clinical specimens have shown that this new PR antibody outperforms the best mouse monoclonal antibody currently available in the market. The potential therapeutic benefits of humanized versions of this antibody could be significant for assessing PR status in human breast cancer.
The second patent focuses on a high-affinity monoclonal antibody for recognizing the estrogen receptor (ER). Similar to the PR antibody, this lagomorph-derived ER antibody (clone SP1) eliminates the need for target retrieval in immunohistochemistry. It also exhibits a low background, which enhances its effectiveness. Comparative studies indicate that the new ER antibody has favorable results compared to existing mouse monoclonal ER antibodies. This innovation may also provide therapeutic benefits through humanized versions of the ER antibody.
Career Highlights
Haiying Xia is currently employed at Spring Bioscience Corporation, where he continues to advance his research in monoclonal antibodies. His work has garnered attention for its potential impact on breast cancer diagnostics and treatment.
Collaborations
One of his notable collaborators is Zhida Huang, who contributes to the research efforts at Spring Bioscience Corporation.
Conclusion
Haiying Xia's innovative work in developing high-affinity monoclonal antibodies represents a significant advancement in the field of immunology. His contributions may lead to improved diagnostic tools and therapeutic options for breast cancer patients.